Immunotech Biopharm Ltd
Company Profile
Business description
Immunotech Biopharm Ltd is a cellular immunotherapy biopharmaceutical company in China. The company is focused on the research, development, and commercialization of T-cell immunotherapy. Its product EAL is a multi-target cellular immunotherapy product for the treatment of various types of cancer. Its product pipeline features classes of cellular immunotherapy products, including both non-genetically modified and genetically modified products, as well as both multi-target and single-target products. Its other products include the CAR-T cell series and the TCR-T cell series.
Contact
No.1 Kangding Street
8th Floor, Block 1, Guosheng Technology Park
Beijing Economic-technological Development Area
Beijing100176
CHNT: +86 8610884002
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
154
Stocks News & Analysis
stocks
Wildly overvalued ASX stock is skating on thin ice
stocks
Uber flexes its network effect and delivers strong result
stocks
Ask the analyst: Are Qantas shares a value trap?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,098.30 | 12.80 | -0.14% |
CAC 40 | 7,635.03 | 13.99 | 0.18% |
DAX 40 | 23,924.36 | 78.29 | 0.33% |
Dow JONES (US) | 44,193.12 | 81.38 | 0.18% |
FTSE 100 | 9,164.31 | 21.58 | 0.24% |
HKSE | 25,051.16 | 140.53 | 0.56% |
NASDAQ | 21,169.42 | 252.87 | 1.21% |
Nikkei 225 | 41,032.65 | 237.79 | 0.58% |
NZX 50 Index | 12,887.10 | 6.94 | 0.05% |
S&P 500 | 6,345.06 | 45.87 | 0.73% |
S&P/ASX 200 | 8,828.10 | 15.60 | -0.18% |
SSE Composite Index | 3,640.55 | 6.56 | 0.18% |